Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

BACKGROUND: Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have developed the first active vaccine against the C-termin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacosta, Ana-María, Pascual-Lucas, María, Pesini, Pedro, Casabona, Diego, Pérez-Grijalba, Virginia, Marcos-Campos, Iván, Sarasa, Leticia, Canudas, Jesus, Badi, Hassnae, Monleón, Inmaculada, San-José, Itziar, Munuera, Josep, Rodríguez-Gómez, Octavio, Abdelnour, Carla, Lafuente, Asunción, Buendía, Mar, Boada, Mercè, Tárraga, Lluis, Ruiz, Agustín, Sarasa, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789644/
https://www.ncbi.nlm.nih.gov/pubmed/29378651
http://dx.doi.org/10.1186/s13195-018-0340-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789644/
https://www.ncbi.nlm.nih.gov/pubmed/29378651
http://dx.doi.org/10.1186/s13195-018-0340-8

Ejemplares similares